MARKET

VIRX

VIRX

Viracta Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.110
+0.040
+1.93%
After Hours: 2.160 +0.05 +2.37% 16:27 05/20 EDT
OPEN
2.130
PREV CLOSE
2.070
HIGH
2.130
LOW
1.980
VOLUME
171.04K
TURNOVER
0
52 WEEK HIGH
13.08
52 WEEK LOW
1.820
MARKET CAP
79.10M
P/E (TTM)
-1.7128
1D
5D
1M
3M
1Y
5Y
Stocks That Hit 52-Week Lows On Monday
  On Monday, 198 companies reached new 52-week lows.
Benzinga · 5d ago
Viracta Therapeutics to Present at Upcoming May Investor Conferences
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management will present and participate in one-on-one meetings at the following investor conferences in May:
PR Newswire · 05/11 20:05
Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-Barr Virus-Positive Solid Tumors
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, will host a key opinion leader (KOL) webinar on Nana-val (nanatinostat and valganciclovir) for the treatment of advanced Epstein-Barr virus-pos...
PR Newswire · 04/20 15:58
VIRX, ARQQ and GWGH among mid-day movers
Gainers: Casa Systems (CASA) +67%. CEL-SCI Corporation (CVM) +55%. Natus Medical (NTUS) +29%. Frequency Therapeutics (FREQ) +26%. GWG Holdings (GWGH) +20%. IMARA (IMRA) +19%. Iveda Solutions (IVDA) +18%. AgriFORCE (AGRI) +18%. Maris-Tech
Seekingalpha · 04/18 16:37
34 Stocks Moving In Monday's Mid-Day Session
Gainers Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions.
Benzinga · 04/18 16:13
CTRM, VIRX and CYTO among mid-day movers
Gainers: Veru (VERU) +196%. Hoth Therapeutics (HOTH) +126%. Altamira Therapeutics (CYTO) +54%. Iveda Solutions (IVDA) +37%. VNET Group (VNET) +30%. SailPoint Technologies Holdings (SAIL) +29%. Castor Maritime (CTRM) +25%. Datto
Seekingalpha · 04/11 16:44
Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is scheduled to present at the 21st Annual Needham Virtual Healthcare Conference, on Wednesday, April 1...
PR Newswire · 04/07 14:13
Viracta Therapeutics Announces New Employment Inducement Grant
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the Compensation Committee of Viracta's Board of Directors approved the grant of non-qualified stock options to a new non-...
PR Newswire · 03/18 20:10
More
No Data
Learn about the latest financial forecast of VIRX. Analyze the recent business situations of Viracta Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VIRX stock price target is 21.40 with a high estimate of 36.00 and a low estimate of 10.00.
High36.00
Average21.40
Low10.00
Current 2.110
EPS
Actual
Estimate
-0.34-0.26-0.17-0.09
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 105
Institutional Holdings: 19.56M
% Owned: 52.17%
Shares Outstanding: 37.49M
TypeInstitutionsShares
Increased
15
1.39M
New
13
618.98K
Decreased
22
1.68M
Sold Out
12
1.90M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.64%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
President/Chief Executive Officer
Ivor Royston
Chief Financial Officer/Chief Operating Officer/Secretary
Daniel Chevallard
Executive Vice President/Chief Scientific Officer
Judith Fox
Other
Lisa Rojkjaer
Independent Director
Jane Barlow
Independent Director
Flavia Borellini
Independent Director
Nicole Onetto
Independent Director
Stephen Rubino
Independent Director
Barry Simon
No Data
No Data
About VIRX
Viracta Therapeutics, Inc., formerly Sunesis Pharmaceuticals, Inc., is a precision oncology company. The Company is focused on the development of new medicines targeting virus-associated malignancies. The Company conducts clinical trials for its combination product candidate as a therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The Company is conducting three clinical trials for its lead product candidate, Nana-val, in EBV+ lymphomas and solid tumors, including a Phase II registrational trial of Nana-val in EBV+ lymphomas. Its lead product candidate is an all-oral combination of nanatinostat. Its development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510, a preclinical-stage PDK-1 inhibitor. Its novel synthetic lethality approach targets the EBV genome to enable the killing of the tumor cells by inducing the expression of certain viral kinase genes which in-turn activate an antiviral drug.

Webull offers kinds of Viracta Therapeutics Inc stock information, including NASDAQ:VIRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIRX stock methods without spending real money on the virtual paper trading platform.